Logo image of APYX

APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

USA - NASDAQ:APYX - US03837C1062 - Common Stock

3.13 USD
+0.21 (+7.19%)
Last: 10/20/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to APYX. APYX was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of APYX have multiple concerns. APYX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year APYX has reported negative net income.
APYX had a negative operating cash flow in the past year.
In the past 5 years APYX always reported negative net income.
APYX had a negative operating cash flow in each of the past 5 years.
APYX Yearly Net Income VS EBIT VS OCF VS FCFAPYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

APYX has a Return On Assets of -29.66%. This is comparable to the rest of the industry: APYX outperforms 44.21% of its industry peers.
With a Return On Equity value of -237.96%, APYX is not doing good in the industry: 74.21% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -29.66%
ROE -237.96%
ROIC N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
APYX Yearly ROA, ROE, ROICAPYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 61.63%, APYX is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
APYX's Gross Margin has declined in the last couple of years.
APYX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
APYX Yearly Profit, Operating, Gross MarginsAPYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

More info and screens

3

2. Health

2.1 Basic Checks

APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APYX has more shares outstanding
The number of shares outstanding for APYX has been increased compared to 5 years ago.
APYX has a worse debt/assets ratio than last year.
APYX Yearly Shares OutstandingAPYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
APYX Yearly Total Debt VS Total AssetsAPYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

APYX has an Altman-Z score of 0.15. This is a bad value and indicates that APYX is not financially healthy and even has some risk of bankruptcy.
APYX's Altman-Z score of 0.15 is in line compared to the rest of the industry. APYX outperforms 44.74% of its industry peers.
A Debt/Equity ratio of 4.74 is on the high side and indicates that APYX has dependencies on debt financing.
The Debt to Equity ratio of APYX (4.74) is worse than 87.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.74
Debt/FCF N/A
Altman-Z 0.15
ROIC/WACCN/A
WACC9.21%
APYX Yearly LT Debt VS Equity VS FCFAPYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

APYX has a Current Ratio of 4.72. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of APYX (4.72) is better than 75.79% of its industry peers.
APYX has a Quick Ratio of 3.95. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
APYX has a better Quick ratio (3.95) than 74.21% of its industry peers.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 3.95
APYX Yearly Current Assets VS Current LiabilitesAPYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.12% over the past year.
Looking at the last year, APYX shows a decrease in Revenue. The Revenue has decreased by -5.15% in the last year.
The Revenue has been growing by 11.24% on average over the past years. This is quite good.
EPS 1Y (TTM)45.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.63%
Revenue 1Y (TTM)-5.15%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%-6.39%

3.2 Future

APYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.24% yearly.
The Revenue is expected to grow by 41.40% on average over the next years. This is a very strong growth
EPS Next Y43.67%
EPS Next 2Y16.64%
EPS Next 3Y14.8%
EPS Next 5Y18.24%
Revenue Next Year5.76%
Revenue Next 2Y5.36%
Revenue Next 3Y6.31%
Revenue Next 5Y41.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APYX Yearly Revenue VS EstimatesAPYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
APYX Yearly EPS VS EstimatesAPYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APYX Price Earnings VS Forward Price EarningsAPYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APYX Per share dataAPYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

APYX's earnings are expected to grow with 14.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.64%
EPS Next 3Y14.8%

More info and screens

0

5. Dividend

5.1 Amount

APYX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APYX MEDICAL CORP

NASDAQ:APYX (10/20/2025, 8:00:00 PM)

3.13

+0.21 (+7.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners42.84%
Inst Owner Change0.85%
Ins Owners14.55%
Ins Owner Change0%
Market Cap118.38M
Analysts77.78
Price Target4.08 (30.35%)
Short Float %0.73%
Short Ratio3.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.88%
Min EPS beat(2)5.46%
Max EPS beat(2)18.3%
EPS beat(4)4
Avg EPS beat(4)19.07%
Min EPS beat(4)5.46%
Max EPS beat(4)26.47%
EPS beat(8)5
Avg EPS beat(8)1.82%
EPS beat(12)6
Avg EPS beat(12)-3.78%
EPS beat(16)9
Avg EPS beat(16)1.59%
Revenue beat(2)0
Avg Revenue beat(2)-3.11%
Min Revenue beat(2)-4.69%
Max Revenue beat(2)-1.52%
Revenue beat(4)1
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)4.14%
Revenue beat(8)3
Avg Revenue beat(8)-2.89%
Revenue beat(12)4
Avg Revenue beat(12)-4.23%
Revenue beat(16)7
Avg Revenue beat(16)-1.16%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.5%
EPS NQ rev (3m)-6.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.78%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)2.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.55
P/FCF N/A
P/OCF N/A
P/B 16.32
P/tB 16.32
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS1.23
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.66%
ROE -237.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.63%
FCFM N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
F-Score3
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 4.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 129.14%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 3.95
Altman-Z 0.15
F-Score3
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)103.68%
Cap/Depr(5y)91.24%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.63%
EPS Next Y43.67%
EPS Next 2Y16.64%
EPS Next 3Y14.8%
EPS Next 5Y18.24%
Revenue 1Y (TTM)-5.15%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%-6.39%
Revenue Next Year5.76%
Revenue Next 2Y5.36%
Revenue Next 3Y6.31%
Revenue Next 5Y41.4%
EBIT growth 1Y45.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.7%
EBIT Next 3Y19.61%
EBIT Next 5Y28.09%
FCF growth 1Y41.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.97%
OCF growth 3YN/A
OCF growth 5YN/A